BioNTech SE (NASDAQ:BNTX - Get Free Report) shares were up 4.9% on Tuesday . The company traded as high as $107.39 and last traded at $106.85. Approximately 392,585 shares traded hands during trading, a decline of 51% from the average daily volume of 805,357 shares. The stock had previously closed at $101.87.
Analysts Set New Price Targets
A number of analysts recently weighed in on the company. Hsbc Global Res upgraded BioNTech from a "hold" rating to a "strong-buy" rating in a report on Friday, August 2nd. Jefferies Financial Group upgraded shares of BioNTech from a "hold" rating to a "buy" rating and raised their price target for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Berenberg Bank initiated coverage on BioNTech in a report on Tuesday. They issued a "buy" rating and a $130.00 target price for the company. UBS Group upped their price objective on shares of BioNTech from $97.00 to $131.00 and gave the company a "neutral" rating in a report on Wednesday, September 18th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $171.00 price target on shares of BioNTech in a report on Thursday, November 14th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $138.79.
Check Out Our Latest Stock Report on BioNTech
BioNTech Price Performance
The business has a 50 day simple moving average of $113.57 and a two-hundred day simple moving average of $97.36. The firm has a market capitalization of $25.51 billion, a P/E ratio of -50.79 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. During the same quarter in the previous year, the company earned $0.73 EPS. The business's quarterly revenue was up 38.9% compared to the same quarter last year. On average, sell-side analysts expect that BioNTech SE will post -3.68 EPS for the current fiscal year.
Institutional Trading of BioNTech
Several hedge funds and other institutional investors have recently bought and sold shares of BNTX. Janney Montgomery Scott LLC bought a new position in shares of BioNTech during the 1st quarter valued at $314,000. ProShare Advisors LLC grew its position in shares of BioNTech by 10.4% in the 1st quarter. ProShare Advisors LLC now owns 6,785 shares of the company's stock worth $626,000 after buying an additional 637 shares during the period. Covestor Ltd increased its stake in shares of BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after acquiring an additional 133 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in BioNTech by 79.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,426 shares of the company's stock worth $316,000 after purchasing an additional 1,518 shares during the period. Finally, Crewe Advisors LLC purchased a new position in shares of BioNTech during the first quarter valued at approximately $75,000. Hedge funds and other institutional investors own 15.52% of the company's stock.
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
